Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.

Trial Details

NCT ID
NCT06711471
Phase
PHASE2
Sponsor
LIN YANG
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with histopathological confirmed gastric/GEJ adenocarcinoma.
  • The clinical stage was IV, according to AJCC 8th edition.
  • Patients had received at least two systematic therapies.
  • Patients had received or not received immunotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →